Brazil forges ahead in anti-graft fight
This article was originally published in Clinica
Medical technology companies operating in Brazil can expect to see the implementation of additional measures relating to anti-bribery rules in the country.
You may also be interested in...
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.